welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Development of Late-Stage CPP-1X/Sulindac Combination for Familial Adenomatous Polyposis
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP).
expertly curated content related to this topic
- kirsten doumaPostdoc at Academic Medical Center...
- Berberine Potently Attenuates Intestinal Polyps Growth in ApcMin Mice and Familial Adenomatous Polyposis Patients Th...As a traditional anti-inflammatory Chine...
- Marc S. Greenblatt, MDProfessor of Medicine, Hematology/Oncolo...
- Todd SpurrierThe mission of DESTINATION X RIDE (DXR) ...
- emmanouil saloustrosHereditary cancer clinic at University h...
- Christine K. Barth, MA, LCGCGenetic CounselorSkills: EMR, Clinic...
- Sarah Adelsperger, MS, LCGCSarah Adelsperger, MS, LCGC, is a board-...
English
Portuguese